Oxeia Biopharma

Oxeia Biopharmaceuticals, Inc. is a clinical stage biotech company developing drug treatments for concussions and acute neurotrauma. Rest is not enough!

[Oxeia Biopharma @oxeiabio]

5 days until Oxeia goes live on the question that defines this entire field:

Why do millions of Americans develop persistent concussion symptoms every year—and walk away with nothing but a prescription to rest?

That's what this program is built to change. Michael Wyand, Dr. Vishal Bansal, and Alex Smith will walk through the science, the clinical data, and what Phase 2b is designed to test. If you haven't registered yet, now's the time.

📅 Thursday, June 18 · 11 AM PT / 2 PM ET

Reserve your spot: https://t.co/YkSOUtwwRl

OXE103 is investigational. Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

Most concussion patients are told to rest.

Not this.

In 6 days, Michael Wyand, Dr. Vishal Bansal, and Alex Smith are going live to walk through where OXE103 stands—the investigational therapy that showed an 85% responder rate in Phase 2a, in a condition with zero FDA-approved treatments.

It's live. And it's the most direct look inside this program we've offered.

📅 Thursday, June 18 · 11 AM PT / 2 PM ET

Reserve your spot: https://t.co/YkSOUtx4GT

OXE103 is investigational. Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

“I remember throwing completely blind. And somehow we scored.”

That was Alex Smith’s last play of the 2012 season. He came off the field. Colin Kaepernick took over. The 49ers went to the Super Bowl. Alex watched from the sideline.

He went live on StartEngine on June 3 to talk about that concussion, the treatment that hasn’t changed in 100 years, and why he’s backing OXE103. Stream is up — link in bio.

#concussion #biotech #braininjury #startengine #NFL #footballmom #hockeymom #soccermom #youthsports

OXE103 is investigational. Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

Save the date: live investor webinar, June 18 (11am PT / 2pm ET).

Join Oxeia CEO Dr. Michael Wyand, Co-Founder & CSO Dr. Vishal Bansal, and board member Alex Smith (former NFL QB) for a live discussion on OXE103—and live Q&A.

Register: https://t.co/YkSOUtx4GT

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk. OXE103 is investigational.

[Oxeia Biopharma @oxeiabio]

A short message from Alex Smith, Oxeia board member and former NFL quarterback.

Alex is right. In 2026 there is still no FDA-approved drug for concussion. OXE103 is one of the few in development. Phase 2a at the University of Kansas Medical Center showed an 85% responder rate. Phase 2b is a 160-patient, multi-site, randomized, placebo-controlled trial planned for later this year.

Explore the Offering: https://t.co/PTjQSf8Q5e

Reg CF via StartEngine Primary LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

Can we finally treat concussions instead of just telling patients to "rest"?

Michael Wyand w/ Chris Lustrino (@kingscrowdinc ) on Inside Startup Investing.

85% responder rate (Phase 2a) + 300+ treated patients (estimated 5-7 yr head start) + Phase 2b next.

Listen: https://t.co/kpf9FREUk5

Deal page: https://t.co/l00KC6QJn0

Reg CF via @StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

Alex Smith on Concussion Alliance, on the state of concussion medicine today: "There's nothing. There is nothing. It is a giant nothing. No treatment. Just nothing. Rest and wait."

That's the gap behind OXE103.

Listen 👉 https://t.co/EyjWwBLqPR

Learn how to invest 👉 https://t.co/PTjQSf9nUM

Reg CF via StartEngine Primary (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

In 2026, there's still no FDA-approved drug to treat concussion.

Girls tend to have more severe, longer-lasting concussion symptoms than boys, and we're unclear on why.

Our CSO Dr. Vishal Bansal on Troy Talks (Fox 5 KUSI Now), on the work behind OXE103.

Watch → https://t.co/bdp1xkd951

Learn how to invest → https://t.co/PTjQSf9nUM

Reg CF via StartEngine Primary (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

Memorial Day is for the ones who didn't come home.

From our CEO Michael Wyand:

"The injuries we still don't have good answers for are often the ones you can't see. The headaches that don't go away. The memory issues."

So many trace back to concussion, and too many veterans are still living with them. That's the gap we're working to close.

To every service member, veteran, Gold Star family, and military family: thank you.

Explore the offering → https://t.co/PTjQSf8Q5e

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

Today. 11am PT / 2pm ET.

Our CEO live on the StartEngine app. Zero FDA drugs exist for concussion. He'll walk through why and what's next.

Search "StartEngine" → download → turn on notifications.

[Oxeia Biopharma @oxeiabio]

Tonight: our CSO on Fox 5 KUSI Now.

8pm PT. Our Chief Scientific Officer Dr. Vishal Bansal sits down to answer the concussion question almost nobody is answering: in 2026, why is there still not a single FDA-approved drug to treat it.

Watch on the Fox 5 KUSI Now app—Apple TV, Fire TV, Roku.

→ https://t.co/PTjQSf9nUM

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

🏆 Two years running.

Oxeia named Most Innovative mTBI Company 2026 by Global Health & Pharma. For OXE103, our concussion drug.

Still zero FDA-approved drugs for concussion. That's what we're working to change.

→ https://t.co/PTjQSf8Q5e

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

Tuesday: our CEO goes live on the StartEngine app.

May 19, 11am PT / 2pm ET. Dr. Michael Wyand on Phase 2a, the years of development we skipped, and the path to the first FDA-approved treatment for concussion. Live Q&A.

To join: search "StartEngine" on the App Store or Google Play, then turn on notifications.

@OxeiaBiopharma

→ https://t.co/dpvjxycx6R

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

One paper started Oxeia.

"And that was my aha moment."

Our co-founder Dr. Vishal Bansal on the Life After Impact podcast. The balance-beam mice, the Phase 2a trial with an 85% responder rate, and the path to the first FDA-approved drug for concussion.

🎧 Full episode: https://t.co/gbH80yQozf

→ https://t.co/PTjQSf8Q5e

Episode courtesy of Life After Impact with Dr. Ayla Wolf.

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

#Concussion #TBI #LifeAfterImpact

[Oxeia Biopharma @oxeiabio]

Every practice and every game is an exposure. One high school football team, 30 kids, five sessions a week, 10-week season: about 1,500 exposures. At the concussion rates published by MedLink Neurology, 1 to 3 of those kids will have a concussion.

Multiply across every contact sport in the country. 1.1 to 1.9 million youth concussions a year. No FDA-approved treatment. Ever.

Do the math.

→ https://t.co/PTjQSf8Q5e

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

1.6–3.8M athlete concussions a year. Zero FDA-approved drugs.

The playbook has 4 plays: Recognize. Remove. Rest. Return to play.

There's no Play 5: Treat.

@OxeiaBiopharma is writing the missing page. 85% responder rate in Phase 2a.

Swipe the playbook 👉

→ https://t.co/PTjQSf9nUM

#concussion #TBI

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

The concussion playbook ends at Play 4: Return to play.

There's no Play 5: Treat. 1.6–3.8M athletes a year. Zero FDA-approved drugs.

@OxeiaBiopharma is writing the missing page. 85% responder rate in Phase 2a.

Invest: https://t.co/PTjQSf8Q5e

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

"It's like draining the battery. And that happens instantaneously."

Our CEO on what a concussion actually does to your brain and why there's still no drug to treat it. OXE103 is working to change that.

🎧 Full episode: https://t.co/9D8HcXCacA

Podcast courtesy of The Innovation Blueprint and Webisoft.

[Oxeia Biopharma @oxeiabio]

7 out of 10 ER visits for sports TBIs: kids under 17. Girls' soccer is #2 on the CDC concussion list. This isn't a football problem.

Same treatment for every sport, every athlete: rest and wait. Zero FDA-approved drugs. @OxeiaBiopharma is working to change that.

→ Invest now: https://t.co/PTjQSf9nUM

Reg CF via StartEngine Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.

[Oxeia Biopharma @oxeiabio]

April is National Youth Sports Safety Month.

Better awareness. Better protocols. Better helmets. Still zero FDA-approved treatments for persistent concussion symptoms.

The protection is improving. Treatment is what comes next. @OxeiaBiopharma is working to change that.

https://t.co/PTjQSf9nUM

Reg CF via @StartEngineLA Primary, LLC (FINRA/SIPC). Speculative, illiquid, high risk.